Leena Gandhi named head of Lilly Oncology I-O medical development

2 May 2018

US pharma major Eli Lilly (NYSE: LLY) today announced that Leena Gandhi, a prestigious thoracic oncologist with a focus on immunotherapy and early drug development, will join Lilly Oncology on June 25, 2018 to lead immuno-oncology medical development.

Dr Gandhi is currently the director of thoracic medical oncology and an associate professor of medicine at the New York University (NYU) School of Medicine. After joining Lilly, she will lead a team of scientists that oversees the Lilly Oncology immunotherapy portfolio. She will report to Kimberly Blackwell, vice president of early phase development and immuno-oncology.

"Dr Gandhi is highly regarded for her experience in thoracic oncology and immunotherapy, having worked in early drug development at Dana-Farber Cancer Institute and now leading the thoracic medical oncology program at NYU," said Dr Blackwell. "We know that her expertise and innovative thinking will lead to significant progress for patients facing cancer through the use of immune therapies. We are thrilled to have Dr Gandhi join us at Lilly."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK